FDA Authorizes Gohibic (vilobelimab) for COVID-19 Treatment
The FDA has authorized Gohibic (vilobelimab) injection for the treatment of COVID-19.
Asset / Drug
Drug and asset intelligence for Gohibic with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.